Yu Jiang

Dr. Yu Jiang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Human Genetics and Genomics Advances
Verified
Journal Article
Open access
YJYu Jiang
Yu Jiang
TMTravis J. Meyers
Travis J. Meyers
AEAdaeze A. Emeka
Adaeze A. Emeka
LCLauren Folgosa Cooley
Lauren Folgosa Cooley
PCPhillip R. Cooper
Phillip R. Cooper
JWJohn S. Witte
John S. Witte
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for PC, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 5,222 PC patients and 1,139 other patients from replication cohorts, all of whom initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 variants associated with conversion, 15 of which were not previously associated with PC risk. With a transcriptome-wide association study (TWAS), we found two genes associated with conversion (MAST3, p = 6.9 × 10−7 and GAB2, p = 2.0 × 10−6). Moreover, increasing values of a previously validated 269-variant genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% confidence interval [CI] = 0.94–1.36); whereas decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04–1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS—versus treatment for the initial management of patients with low-risk PC.

10 February 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
THThomas J. Hoffmann
Thomas J. Hoffmann
RGRebecca Graff
Rebecca Graff
RMRavi K. Madduri
Ravi K. Madduri
ARAlex A. Rodriguez
Alex A. Rodriguez
CCClinton L. Cario
Clinton L. Cario
JWJohn S. Witte
John S. Witte
We conducted a multiancestry genome-wide association study of prostate-specific antigen (PSA) levels in 296,754 men (211,342 European ancestry, 58,236 African ancestry, 23,546 Hispanic/Latino and 3,630 Asian ancestry; 96.5% of participants were from the Million Veteran Program). We identified 318 independent genome-wide significant (P ≤ 5 × 10−8) variants, 184 of which were novel. Most demonstrated evidence of replication in an independent cohort (n = 95,768). Meta-analyzing discovery and replication (n = 392,522) identified 447 variants, of which a further 111 were novel. Out-of-sample variance in PSA explained by our genome-wide polygenic risk scores ranged from 11.6% to 16.6% for European ancestry, 5.5% to 9.5% for African ancestry, 13.5% to 18.2% for Hispanic/Latino and 8.6% to 15.3% for Asian ancestry and decreased with increasing age. Midlife genetically adjusted PSA levels were more strongly associated with overall and aggressive prostate cancer than unadjusted PSA levels. Our study highlights how including proportionally more participants from underrepresented populations improves genetic prediction of PSA levels, offering potential to personalize prostate cancer screening.

24 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
CDConor Driscoll
Conor Driscoll
JRJordan M. Rich
Jordan M. Rich
DIDylan Isaacson
Dylan Isaacson
JNJoseph Nicolas
Joseph Nicolas
YJYu Jiang
Yu Jiang
SKShilajit D. Kundu
Shilajit D. Kundu
Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications

5 October 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
YJYu Jiang
Yu Jiang
TSThomas Swain
Thomas Swain
NGNayoon Gim
Nayoon Gim
MBMarian Blazes
Marian Blazes
CDChristine Mac Donald
Christine Mac Donald
CLCecilia S. Lee
Cecilia S. Lee

31 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
YJYu Jiang
Yu Jiang
TMTravis J. Meyers
Travis J. Meyers
AEAdaeze A. Emeka
Adaeze A. Emeka
LCLauren Folgosa Cooley
Lauren Folgosa Cooley
PCPhillip R. Cooper
Phillip R. Cooper
JWJohn S. Witte
John S. Witte
Men diagnosed with low-risk prostate cancer (PC) are increasingly electing active surveillance (AS) as their initial management strategy. While this may reduce the side effects of treatment for prostate cancer, many men on AS eventually convert to active treatment. PC is one of the most heritable cancers, and genetic factors that predispose to aggressive tumors may help distinguish men who are more likely to discontinue AS. To investigate this, we undertook a multi-institutional genome-wide association study (GWAS) of 6,361 PC patients who initially elected AS and were followed over time for the potential outcome of conversion from AS to active treatment. In the GWAS we detected 18 single nucleotide polymorphisms (SNPs) associated with conversion, 15 of which were not previously associated with PC risk. We found two genes associated with conversion ( MAST3 , p = 6.9×10 -7 and GAB2 , p = 2.0×10 -6 ). Moreover, increasing values of a previously validated 269-SNP genetic risk score (GRS) for PC was positively associated with conversion (e.g., comparing the highest to the two middle deciles gave a hazard ratio [HR] = 1.13; 95% Confidence Interval [CI]= 0.94-1.36); whereas, decreasing values of a 36-variant GRS for prostate-specific antigen (PSA) levels were positively associated with conversion (e.g., comparing the lowest to the two middle deciles gave a HR = 1.25; 95% CI, 1.04-1.50). These results suggest that germline genetics may help inform and individualize the decision of AS—or the intensity of monitoring on AS— versus treatment for the initial management of patients with low-risk PC.

12 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NGNayoon Gim
Nayoon Gim
IGIn Gim
In Gim
YJYu Jiang
Yu Jiang
YKYuka Kihara
Yuka Kihara
MBMarian Blazes
Marian Blazes
ALAaron Y Lee
Aaron Y Lee
Acquiring insights from electronic health records (EHRs) is slowed by manual analytical workflows that limit scalability and reproducibility. We present LATCH (LLM-Assisted Testing of Clinical Hypotheses), an agentic framework that converts natural language clinical hypotheses into fully auditable analyses on structured EHR data. LATCH integrates LLM-assisted semantic layers with deterministic execution pipelines to automate cohort construction, statistical analysis, and result reporting, while isolating patient-level data from LLM-involved steps. Using diabetes as a model disease, LATCH reproduced findings from 20 published studies within 3-15 minutes per study. Beyond replication, LATCH enabled study extensions and new insight generation through simple natural language hypothesis modifications. We demonstrated LATCH across 102 hypothesis tests spanning reproduction, extension, and insight generation. We systematically stress-tested LATCH to characterize its limitations and operational boundaries. LATCH provides a scalable framework for reproducible real-world evidence generation, reducing analytical bottlenecks and improving reliability of AI-assisted biomedical discovery while preserving human oversight.